Shares in GlaxoSmithKline and AstraZeneca have historically moved in lock-step. But over the past 12 months there's been a 20% relative decline in the latter, which I think looks unjustified (though not all my MoneyWeek colleagues agree seeGlaxo:a better bet than AstraZenecafor an alternative take).
AstraZeneca closed December with net funds of $2.8bn, which should support its planned $4.5bn buyback programme and 6% yield. Ageing populations and the rise of personalised medicine mean the firm also has plenty of opportunities to exploit. So why are investors pessimistic?
At its financial results presentation in February, the chief executive, David Brennan, said that he expects earnings per share (EPS) to fall 14%-18% this year to $6.00-$6.30, primarily due to the expiry of patents on key drugs and government price squeezes.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Its anti-psychotic medicine Seroquel will lose exclusivity in the US in March, and goes off patent in Europe later in 2012. New cardiovascular drug Brilinta is off to a slow start and cholesterol buster Crestor is facing more competition following the arrival of cheap generic versions of Pfizer's market-leading Lipitor.
Patent expiries and tighter fiscal spending plans reduced sales by $3bn in 2011 to $33.6bn. By 2016, analysts worry that AstraZeneca could see up to 25% (or $8bn) of its top line disappear. But cutting another 7,300 jobs should deliver an extra $1.6bn in annual savings by the end of 2014.
AstraZeneca (LSE: AZN), rated a BUY by Panmure Gordon
The pipeline is being replenished after a couple of late-stage failures, including the delay of diabetes treatment dapagliflozin, developed with partner Bristol-Myers Squibb.
There are 86 new compounds either passing through clinical trials or that have already been submitted to the regulatory authorities. Brennan reckons these factors combined will add $2bn-$4bn to turnover by 2014. So revenues should "remain in the range of $28bn-$34bn over 2010-2014". Core operating profit margins before research and development (R&D) expenses will stay in the range of 48%-54%, compared to 54% in 2011.
Even if the drugs pipeline broke down, I still reckon the stock is worth about £25 a share. And with a large cash pile for fill-in acquisitions, its prospects are nowhere near as dire as the depressed rating suggests. I rate it on a 2.5 times multiple of future sales, which generates an intrinsic worth of £34 a share. First-quarter results are due out on 26 April. Panmure has a target price of £36.
Rating: BUY at £29
Paul Hill also writes a weekly share-tipping newsletter, Precision Guided Investments. See www.moneyweek.com/PGI or phone 020-7633 3634 for more.
Paul gained a degree in electrical engineering and went on to qualify as a chartered management accountant. He has extensive corporate finance and investment experience and is a member of the Securities Institute.
Over the past 16 years Paul has held top-level financial management and M&A roles for blue-chip companies such as O2, GKN and Unilever. He is now director of his own capital investment and consultancy firm, PMH Capital Limited.
Paul is an expert at analysing companies in new, fast-growing markets, and is an extremely shrewd stock-picker.
King Charles banknotes to enter circulation in June
New banknotes featuring the King will enter circulation on 5 June – here’s what they will look like and what you need to know about your old notes.
By Katie Williams Published
Metro Bank to slash 5.22% savings rate for current customers- what’s the next best alternative?
Metro Bank is set to cut the rate on its best buy instant access saver for existing customers. Is there an alternative on the market and should you switch now?
By Vaishali Varu Published